We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Decision on Gout Drug Delayed for Routine Inspection
FDA Decision on Gout Drug Delayed for Routine Inspection
January 23, 2009
Takeda Pharmaceutical’s NDA for its gout treatment febuxostat didn’t receive a complete review by the Prescription Drug User Fee Act (PDUFA) deadline.